Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

OTHER 3NIH 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 14Gynecologic 12Lymphoid 11Genitourinary 9CNS 8Other hematologic neoplasm 7Dermatologic 7Other solid neoplasm 4Gastrointestinal 4Thoracic 3Plasma cell 3Breast 3Tumor-Agnostic 1Myeloid 1Head & Neck 1Classical hematology 1

Conditions

Multiple Myeloma 3

Interventions

Dexamethasone 36Melphalan 29Cyclophosphamide 28Specimen Handling 26Biopsy 26Bortezomib 24Calcium Dobesilate 20Magnetic Resonance Spectroscopy 19Lenalidomide 17fludarabine phosphate 15Filgrastim 15Peripheral Blood Stem Cell Transplantation 13Vincristine 12Prednisone 12dexamethasone acetate 11dexamethasone 21-phosphate 11auricularum 11carfilzomib 10Doxorubicin 10sargramostim 9fludarabine 8Thalidomide 8Interferon-alpha 7Cyclosporine 7Busulfan 7trametinib 6ixazomib 6Rituximab 6Etoposide 6daratumumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × temsirolimus × Plasma cell × Clear all
NCT00693433 2015-12-04

Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Completed
15 enrolled
Plasma cell

Multiple Myeloma

NCT00079456 2013-10-11

Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
25 enrolled
Plasma cell

Multiple Myeloma

NCT00398515 2013-09-30

Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Completed
25 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡